NCT01690507View on ClinicalTrials.gov

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

January 31, 2016

Conditions
MDSAML
Interventions
DRUG

Decitabine

20 mg/m²/day for 5 days

DRUG

Cytarabine

DRUG

aclacinomycin

DRUG

Granulocyte colony-stimulating factor

OTHER

HLA haploidentical mononuclear cells infusion

Trial Locations (2)

100048

Navy General Hospital, Beijing

100853

Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

Navy General Hospital, Beijing

OTHER

lead

Chinese PLA General Hospital

OTHER

NCT01690507 - Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | Biotech Hunter | Biotech Hunter